Literature DB >> 29221240

Composite metrics in response assessment-new hope in oesophageal cancer?

Janusz Włodarczyk1, Jarosław Kużdżał1.   

Abstract

Entities:  

Year:  2017        PMID： 29221240      PMCID： PMC5708404          DOI： 10.21037/jtd.2017.08.28

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  10 in total

1.  A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer.

Authors:  John D Urschel; Hari Vasan; Chris J Blewett
Journal:  Am J Surg       Date:  2002-03       Impact factor: 2.565

Review 2.  Neoadjuvant treatment of esophageal cancer.

Authors:  Nicholas P Campbell; Victoria M Villaflor
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

3.  Preoperative chemoradiotherapy for esophageal or junctional cancer.

Authors:  P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast
Journal:  N Engl J Med       Date:  2012-05-31       Impact factor: 91.245

4.  Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemotherapy: The Implications of Metabolic Nodal Response for Personalized Therapy.

Authors:  John M Findlay; Kevin M Bradley; Lai Mun Wang; James M Franklin; Eugene J Teoh; Fergus V Gleeson; Nicholas D Maynard; Richard S Gillies; Mark R Middleton
Journal:  J Nucl Med       Date:  2016-09-15       Impact factor: 10.057

5.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.

Authors:  W A Weber; K Ott; K Becker; H J Dittler; H Helmberger; N E Avril; G Meisetschläger; R Busch; J R Siewert; M Schwaiger; U Fink
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

6.  Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.

Authors:  Katja Ott; Wolfgang A Weber; Florian Lordick; Karen Becker; Raymonde Busch; Ken Herrmann; Hinrich Wieder; Ulrich Fink; Markus Schwaiger; Jörg-Rüdiger Siewert
Journal:  J Clin Oncol       Date:  2006-09-11       Impact factor: 44.544

7.  Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

Authors:  Joel Shapiro; J Jan B van Lanschot; Maarten C C M Hulshof; Pieter van Hagen; Mark I van Berge Henegouwen; Bas P L Wijnhoven; Hanneke W M van Laarhoven; Grard A P Nieuwenhuijzen; Geke A P Hospers; Johannes J Bonenkamp; Miguel A Cuesta; Reinoud J B Blaisse; Olivier R C Busch; Fiebo J W Ten Kate; Geert-Jan M Creemers; Cornelis J A Punt; John Th M Plukker; Henk M W Verheul; Ernst J Spillenaar Bilgen; Herman van Dekken; Maurice J C van der Sangen; Tom Rozema; Katharina Biermann; Jannet C Beukema; Anna H M Piet; Caroline M van Rij; Janny G Reinders; Hugo W Tilanus; Ewout W Steyerberg; Ate van der Gaast
Journal:  Lancet Oncol       Date:  2015-08-05       Impact factor: 41.316

8.  The relationship between the glucose transporter type 1 expression and F-fluorodeoxyglucose uptake in esophageal squamous cell carcinoma.

Authors:  Yukiharu Hiyoshi; Masayuki Watanabe; Yu Imamura; Youhei Nagai; Yoshifumi Baba; Naoya Yoshida; Eiichiro Toyama; Naoko Hayashi; Hideo Baba
Journal:  Oncology       Date:  2009-03-05       Impact factor: 2.935

9.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.

Authors:  Florian Lordick; Katja Ott; Bernd-Joachim Krause; Wolfgang A Weber; Karen Becker; Hubert J Stein; Sylvie Lorenzen; Tibor Schuster; Hinrich Wieder; Ken Herrmann; Rainer Bredenkamp; Heinz Höfler; Ulrich Fink; Christian Peschel; Markus Schwaiger; Jörg R Siewert
Journal:  Lancet Oncol       Date:  2007-09       Impact factor: 41.316

10.  Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival.

Authors:  James M Donahue; Francis C Nichols; Zhuo Li; David A Schomas; Mark S Allen; Stephen D Cassivi; Aminah Jatoi; Robert C Miller; Dennis A Wigle; K Robert Shen; Claude Deschamps
Journal:  Ann Thorac Surg       Date:  2009-02       Impact factor: 4.330
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.